Trials / Conditions / Heterozygous Familial Hypercholesterolemia

Heterozygous Familial Hypercholesterolemia

30 registered clinical trials studyying Heterozygous Familial Hypercholesterolemia — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Early-phase Study of ART002g1 Injection in HeFH: Safety, Tolerability and Preliminary Efficacy NCT07353398	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	EARLY_Phase 1
Recruiting	Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hyperchole NCT06958315	Novartis Pharmaceuticals	—
Recruiting	Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With NCT06634160	Nantes University Hospital	—
Recruiting	A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia NCT06568471	Hasten Biopharmaceutical Co., Ltd.	Phase 3
Enrolling By Invitation	Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Dise NCT06112327	Verve Therapeutics, Inc.	—
Recruiting	A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease NCT06164730	Verve Therapeutics, Inc.	Phase 1
Completed	A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease NCT05398029	Verve Therapeutics, Inc.	Phase 1
Completed	A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolem NCT05325203	Shanghai Junshi Bioscience Co., Ltd.	Phase 3
Completed	Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C NCT04797104	LIB Therapeutics LLC	Phase 3
Completed	Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated NCT04666298	Novartis Pharmaceuticals	Phase 2
Unknown	Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia NCT04759534	Shenzhen People's Hospital	Phase 3
Completed	Safety and Efficacy of IBI306 in HeFH Patients NCT04179669	Innovent Biologics (Suzhou) Co. Ltd.	Phase 3
Completed	A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) NCT04173793	Akeso	Phase 2
Completed	Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C NCT03814187	Novartis Pharmaceuticals	Phase 3
Terminated	Long Term Safety Study of PRALUENT NCT03694197	Regeneron Pharmaceuticals	Phase 4
Completed	Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subject NCT03397121	The Medicines Company	Phase 3
Completed	Lp(a) and Aortic Valve Calcification NCT02976818	Laval University	—
Completed	Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) NCT03038022	Madrigal Pharmaceuticals, Inc.	Phase 2
Completed	Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inh NCT02392559	Amgen	Phase 3
Completed	A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hyp NCT02460159	Organon and Co	Phase 3
Completed	Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Und NCT02326220	Regeneron Pharmaceuticals	Phase 3
Completed	A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial H NCT01968980	Pfizer	Phase 3
Completed	Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who NCT01709500	Regeneron Pharmaceuticals	Phase 3
Terminated	A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterol NCT01583647	Merck Sharp & Dohme LLC	Phase 1
Completed	Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alir NCT01576484	Regeneron Pharmaceuticals	Phase 2
Completed	Exploratory Study of Plaque Regression NCT01515241	Cerenis Therapeutics, SA	Phase 2
Completed	Effects of Soy Protein on Cholesterol Levels in Children Affected With Familial Hypercholesterolemia NCT03563547	Austrian Academic Institute for Clinical Nutrition	N/A
Completed	Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With NCT00706849	Kastle Therapeutics, LLC	Phase 3
Terminated	Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Di NCT00151788	Daiichi Sankyo	Phase 2 / Phase 3
Completed	Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia NCT00171236	Novartis	Phase 3